Cargando…

Recent advances in targeted strategies for triple-negative breast cancer

Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Shuangli, Wu, Yuze, Song, Bin, Yi, Ming, Yan, Yuheng, Mei, Qi, Wu, Kongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464091/ https://www.ncbi.nlm.nih.gov/pubmed/37641116 http://dx.doi.org/10.1186/s13045-023-01497-3

Ejemplares similares

Recent advances and challenges of bispecific antibodies in solid tumors
por: Wu, Yuze, et al.
Publicado: (2021)

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
por: Yi, Ming, et al.
Publicado: (2022)

Focal adhesion kinase: from biological functions to therapeutic strategies
por: Tan, Ximin, et al.
Publicado: (2023)

Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies
por: Zhu, Shuangli, et al.
Publicado: (2021)

Correction to: Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies
por: Zhu, Shuangli, et al.
Publicado: (2022)

Retinal determination gene networks: from biological functions to therapeutic strategies
por: Zhu, Shuangli, et al.
Publicado: (2023)

Recent advances in therapeutic strategies for triple-negative breast cancer
por: Li, Yun, et al.
Publicado: (2022)

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
por: Wu, Yuze, et al.
Publicado: (2022)

Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer
por: Pradhan, Rajesh, et al.
Publicado: (2023)

Recent advances in managing triple-negative breast cancers
por: Bengala, Carmelo
Publicado: (2009)

Triple-negative breast cancer: recent treatment advances
por: Bergin, Alice R T, et al.
Publicado: (2019)

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
por: Yi, Ming, et al.
Publicado: (2022)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Recent advances in nanotheranostics for triple negative breast cancer treatment
por: Thakur, Vikram, et al.
Publicado: (2019)

Overview of recent advances in metastatic triple negative breast cancer
por: O'Reilly, David, et al.
Publicado: (2021)

Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer
por: Shi, Jinhong, et al.
Publicado: (2020)

Increased expression of ECT2 predicts the poor prognosis of breast cancer patients
por: Yi, Ming, et al.
Publicado: (2022)

Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
por: Masci, Domiziana, et al.
Publicado: (2023)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells
por: Yuan, Xun, et al.
Publicado: (2017)

Recent advances of transcriptomics and proteomics in triple‐negative breast cancer prognosis assessment
por: Li, Yuan, et al.
Publicado: (2022)

Novel strategies to target chemoresistant triple-negative breast cancer
por: Venkatesh, Jaganathan, et al.
Publicado: (2020)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
por: Yi, Ming, et al.
Publicado: (2022)

Recent Clinical Advances on Long Non-Coding RNAs in Triple-Negative Breast Cancer
por: Singh, Desh Deepak, et al.
Publicado: (2023)

Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects
por: Khadela, Avinash, et al.
Publicado: (2022)

The nature of triple-negative breast cancer classification and antitumoral strategies
por: Kim, Songmi, et al.
Publicado: (2020)

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
por: Medina, Mauricio A., et al.
Publicado: (2020)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher, Brett, et al.
Publicado: (2016)

Advances of Targeted Therapy for Hepatocellular Carcinoma
por: Niu, Mengke, et al.
Publicado: (2021)

Novel therapeutic strategies for patients with triple-negative breast cancer
por: Zhang, Jun-Fei, et al.
Publicado: (2016)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
por: Li, Chia-Jung, et al.
Publicado: (2021)

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer
por: El Hachem, Georges, et al.
Publicado: (2019)

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
por: Yi, Ming, et al.
Publicado: (2022)

Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer
por: He, Jinsong, et al.
Publicado: (2011)

Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer
por: Wu, Bin, et al.
Publicado: (2020)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
por: Xu, Hanxiao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4m6apieu5ef0o5fehqs1hu78cf